Construction of innovative preemptive medicine for gastrointestinal cancer especially including pancreatic cancer
Description: In the aging society of developed countries, the morbidity of malignant tumors suddenly destroys the "healthy life expectancy". This means, even in a state where one can live independently in a social life, the end of life will come along with the burden close to despair mentally, physically and economically. However, if gastrointestinal cancer can be detected at early phase, could being fully cured.In this study, we showed that abnormal methylation is a universal alteration regardless of the type of cancer and possible to screen gastrointestinal cancer in general, including pancreatic cancer, by detecting fecal DNA methylation. For high-risk people with malignancy, continuously detecting fecal DNA methylation could predict in the early stage of onset without any abnormalities in other laboratory findings with extremely minimally invasive, thus lading the foundation for innovative preemptive medicine that enables.
Amount: ¥6,370,000
Funding type: research
Funder scheme: Grant-in-Aid for Challenging Research (Exploratory)
Start date: 2018-06-29
End date: 2021-03-31
Investigator: TAKESHI NAGASAKA
Institution: Kawasaki Medical School
Funded outputs count: 19
Funder award ID: 18K18464
OpenAlex ID: G8089748401